Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 4/20 | 0.77 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16597 | 0.98 | PKM (0.74) | PKMNPC1RAB9APOLBUSP2 | |
| SCHEMBL5415687 | 0.84 | PKM (0.85) | PKMNPC1RAB9APOLBUSP2 | |
| SCHEMBL2984938 | 0.82 | PKM (0.82) | PKMNPC1RAB9APOLBUSP2 | |
| SCHEMBL16809 | 0.81 | PKM (0.63) | PKMNPC1RAB9APOLBUSP2 | |
| SCHEMBL5830802 | 0.79 | PKM (0.77) | PKMNPC1RAB9APOLBUSP2 | |
| SCHEMBL12092977 | 0.79 | PKM (0.83) | PKMNPC1RAB9APOLBUSP2 | |
| SCHEMBL4699729 | 0.79 | PKM (0.77) | PKMNPC1RAB9APOLBUSP2 | |
| SCHEMBL12656171 | 0.79 | PKM (0.77) | PKMNPC1RAB9APOLBUSP2 | |
| SCHEMBL18037 | 0.79 | PKM (0.59) | PKMNPC1RAB9APOLBUSP2 | |
| SCHEMBL20111 | 0.79 | PKM (0.59) | PKMNPC1RAB9APOLBUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1071680-B1 | N,N-DISUBSTITUTED AMIDES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | ENCYSIVE PHARMACEUTICALS INC (US) | 2008-07-23 | — | — | EP | claimed |
| EP-1071680-A4 | N,N-DISUBSTITUTED AMIDES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORP (US) | 2003-03-05 | — | — | EP | claimed |
| US-6194448-B1 | ANTIINFLAMMATORY AGENTS; ASTHMA; RHEUMATIC DISORDERS | TEXAS BIOTECHNOLOGY CORPORATION | 2001-02-27 | — | — | US | claimed |
| EP-1071680-A1 | N,N-DISUBSTITUTED AMIDES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-01-31 | — | — | EP | claimed |
| WO-1999052898-A1 | N,N-DISUBSTITUTED AMIDES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1999-10-21 | — | — | WO | claimed |
| CN-117720528-A | Oxadiazole sulfonamide compound containing pyrazole structure, and preparation method and application thereof | 贵州大学 | 2024-03-19 | — | — | CN | disclosed |
| CN-112209910-B | Myricetin derivative containing sulfonyl piperazine, preparation method and application | 贵州大学 | 2023-10-17 | — | — | CN | disclosed |
| CN-114634465-B | Pentadienone derivative containing sulfonyl piperazine as well as preparation method and application thereof | 贵州大学 | 2023-05-30 | — | — | CN | disclosed |
| CN-114634465-A | Sulfonyl piperazine-containing pentadiene ketone derivative and preparation method and application thereof | 贵州大学 | 2022-06-17 | — | — | CN | disclosed |
| CN-107286166-B | Substituted 1,3,4, 5-tetrahydro-6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one derivatives | 上海勋和医药科技有限公司 | 2020-03-31 | — | — | CN | disclosed |
| EP-3442533-A1 | TG2 INHIBITOR COMPOUNDS AND USES THEREOF | University Of Ottawa (CA) | 2019-02-20 | — | — | EP | disclosed |
| WO-2017179018-A1 | TG2 INHIBITOR COMPOUNDS AND USES THEREOF | UNIVERSITY OF OTTAWA (CA) | 2017-10-19 | — | — | WO | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| US-20110237583-A1 | 2, 5-DIAMINO-SUBSTITUTED PYRIDO [4, 3-D] PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG | 2011-09-29 | — | — | US | disclosed |
| EP-1071680-B1 | N,N-DISUBSTITUTED AMIDES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | ENCYSIVE PHARMACEUTICALS INC (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1071680-A4 | N,N-DISUBSTITUTED AMIDES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORP (US) | 2003-03-05 | — | — | EP | disclosed |
| US-6262084-B1 | Compounds that inhibit the binding of integrins to their receptors | TEXAS BIOTECHNOLOGY CORPORATION | 2001-07-17 | — | — | US | disclosed |
| US-6194448-B1 | ANTIINFLAMMATORY AGENTS; ASTHMA; RHEUMATIC DISORDERS | TEXAS BIOTECHNOLOGY CORPORATION | 2001-02-27 | — | — | US | disclosed |
| EP-1071680-A1 | N,N-DISUBSTITUTED AMIDES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999052898-A1 | N,N-DISUBSTITUTED AMIDES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1999-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237583-A1 | 2, 5-DIAMINO-SUBSTITUTED PYRIDO [4, 3-D] PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER | ENPP2, PLA2G4A, PLA2G4B | PKM 2712/4885NPC1 4377/4885RAB9A 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.